aap Implantate AG: Capital Increase as part of the performance-improvement program

The Management Board of aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange in the Prime Standard segment, decided today with the Supervisory Board’s approval to increase its capital stock from authorized capital by approx. 5%, or €1,267,357. The new shares are subscribed today, excluding rights entitlement for existing shareholders, by way of a private placement in return for a cash contribution at a price of EUR 1.00. The company’s capital stock thereby increases by EUR 1,267,357 from the present EUR 26,614,513 to EUR 27,881,870.

Within a financing commitment of a shareholder of EUR 2 million and the funds of the above mentioned capital increase, aap obtains a total inflow of approx. EUR 3.3 million. Alongside, aap was able to accomplish a release of a shareholder’s loan of EUR 0.5 million.

These measures serve the purpose of securing the corporate finance and are a component of aap’s performance-improvement program, which include the optimization of the capital structure, cost reduction measures, simplifying the organizational structure, divestiture of non-core business units, pushing a profitable company growth as well as maintaining the existing innovation pace.